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Chromosomal translocations harbored by cancer genomes are important oncogenic
drivers. In MLL rearranged acute leukemia (MLLre) MLL/KMT2A fuses with over 90
partner genes. Mechanistic studies provided clues of MLL fusion protein leukemogenic
potential, but models failed to fully recapitulate the disease. Recently, expression of
oncogenic fusion circular RNAs (f-circ) by MLL-AF9 fusion was proven. This discovery,
together with emerging data on the importance and diversity of circRNAs formed
the incentive to study the circRNAs of the MLL recombinome. Through interactions
with other RNAs, such as microRNAs, and with proteins, circRNAs regulate cellular
processes also related to cancer development. CircRNAs can translate into functional
peptides too. MLL and most of the 90 MLL translocation partners do express circRNAs
and exploration of our RNA-seq dataset of sorted blood cell populations provided new
data on alternative circular isoform generation and expression variability of circRNAs of
the MLL recombinome. Further, we provided evidence that rearrangements of MLL and
three of the main translocation partner genes can impact circRNA expression, supported
also by preliminary observations in leukemic cells. The emerging picture underpins the
view that circRNAs are worthwhile to be considered when studying MLLre leukemias
and provides a new perspective on the impact of chromosomal translocations in cancer
cells at large.
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THE ACUTE LEUKEMIA MLL RECOMBINOME
Cancer genomes often harbor chromosomal translocations and specific rearrangements are
recurrent in specific cancers, most often involving two specific genes or one promiscuous gene
translocated with an array of different genes. In acute leukemia, the MLL gene (official gene
symbol KMT2A) on chromosome 11q23 breaks and fuses with more than 90 translocation partner
genes (TPGs) (Ottersbach et al., 2018), with only a few of them recurrently found in MLL
rearrangements (MLLre).
Genomic studies revealed that MLL fusions are clonal and are considered early initiating
leukemogenic events (Yip and So, 2013; Sanjuan-Pla et al., 2015), and very few additional
mutations are needed to generate infant MLLre (Dobbins et al., 2013). Mechanistic studies
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of particular MLLre showed that fusion proteins are crucial
for transforming potential (Reimer et al., 2017). In addition,
recent data indicated that expression of the wild type KMT2A
is dispensable for MLLre leukemic cells, whereas deletion of
KMT2D alone or in combination with loss of KMT2A reduces
proliferation and induces apoptosis of MLL-AF9 transformed
cells (Chen et al., 2017).
The 2017 survey of the MLL recombinome consortium
(Meyer et al., 2018), based on DNA sequence analysis of 2,345
MLLre acute leukemia cases and literature scrutiny, identified
135 different MLLre involving 94 TPGs, with only a few genes
accounting for most cases. Association of specific partner genes
and/or the breakpoint position with age classes and/or with
leukemia subtypes has been described (Meyer et al., 2018). AF4
is almost exclusively (99%) found in BCP-ALL, whereas AF9 is
slightly more frequent (60%) in myeloid leukemias. Specific MLL
TPGs are detected exclusively in leukemias of the lymphoid (e.g.,
LAF4/AFF3) or of the myeloid lineages (e.g., SEPT6).
MLL breakpoints occur preferentially in three clusters (ex-
in 9, ex-in 10, ex-in 11/12) (van Dongen et al., 1999; de
Jonge et al., 2005). MLL encodes a Lysine Methyltransferase
involved in tissue-specific epigenetic activation of developmental
genes. Most TPGs encode proteins of complexes that affect
transcriptional elongation. Even if the functional effect has not
been investigated for all MLL fusions, MLLre leukemias display
a deeply deregulated epigenetic and transcriptional state, and
the contribution of MLL fusions to leukemia initiation and
evolution, therapy resistance and relapse is still under active
investigation. An array of cellular and animal models generated
to study the leukemogenic mechanisms of MLL fusions furthered
our understanding of MLLre, but failed to fully recapitulate the
human disease features (Ottersbach et al., 2018). The current
state-of-the-art is controversial regarding the cell-of-origin, the
timing and level of MLL fusion protein expression. Even less
is known of the transcripts expressed by MLL fusions. Recent
reports of oncogenic fusion circular RNAs (f-circ) and data
emerging on circular RNAs (circRNAs, transcripts in which the
splice donor site is covalently bound to an upstream acceptor site
by backsplicing) in general made the drawing more complex, but
also very intriguing, and opened a series of new perspectives.
Rearranged cancer genomes (promyelocytic leukemia with
PML-RARα, acute myeloid leukemia with KMT2A-MLLT3 and
a model of the NPM1-ALK fusion) (Guarnerio et al., 2016;
Babin et al., 2018) express f-circ. F-circ include two sequences
not present in the normal genome: the fusion junction, in
which two genomic regions far apart in normal genomes are
juxtaposed, and the backsplice junction, connecting in reverse
order two sequences of the fusion gene. A few studies showed
that f-circ can be oncogenic but only started to disclose involved
mechanisms. Concurrent expression of f-circM9 and MLL-AF9
protein contributed to leukemia progression in in vivo and ex vivo
models, and f-circM9 expression increased drug resistance of
leukemic cells (Guarnerio et al., 2016). F-circ generated from
an EML4-ALK fusion promoted non-small cell lung cancer
development (Tan et al., 2018). The oncogenic potential of f-circ
was linked to mechanisms involving the fusion protein by the
observation that proliferation and TKI resistance of BCR-ABL1
leukemic cells are enhanced by a f-circ that increases the fusion
protein level. Nevertheless, none of these studies investigated the
impact of rearrangements on circRNAs expressed by MLL and
TPGs during normal hematopoiesis. In leukemic cells carrying
translocations beyond generation of f-circ, also ablation or
deregulation of circRNAs will occur with potential contribution
to the disease.
Circularized transcripts of specific genes were reported since
the 80’s, but circRNAs were re-discovered (Salzman et al.,
2012; Memczak et al., 2013, 2015; Bonizzato et al., 2016)
when projects coupling RNA-seq with bioinformatics methods
for reads mapping appropriate to detect backsplicing showed
that thousands of circRNAs are expressed by many genes
with cell type-specific expression regulation (Maass et al.,
2017), and differentiation stage-specificity (Rybak-Wolf et al.,
2015). As reviewed recently (Memczak et al., 2013, 2015;
Bonizzato et al., 2016) circRNAs are abundantly expressed in the
hematopoietic compartment. CircRNAs can play important and
diverse functions, including some typical of non-coding RNAs.
The first function assigned to circRNAs was sponging miRNAs
(Salzman et al., 2012; Memczak et al., 2013, 2015; Bonizzato
et al., 2016) and indirectly regulating miRNA-target expression.
In this way, some circRNAs control key miRNA-involving axes
in normal developmental processes and oncogenesis (Hansen
et al., 2013; Li F. et al., 2015). Other circRNAs regulate cellular
processes by interacting with RNA-binding proteins (Schneider
et al., 2016), scaffolding molecular complexes, as shown for
circFOXO3 that controls cell cycle progression by binding p21
and CDK1 (Du et al., 2016). As long as non-coding RNAs, also
circRNAs have some coding potential, and can be translated into
functional peptides according to recent reports (Legnini et al.,
2017; Pamudurti et al., 2017; Yang et al., 2017).
Taken together these discoveries of circRNA pervasiveness
and functions prompted us to study the circRNAs expressed
by genes of the MLL recombinome (MLL-rec) in normal blood
cells. In this perspective we examined how rearrangements can
result in alteration of sequences and expression level of circRNAs
normally generated by MLL and TPGs, and provided data of
MLLre leukemia in support.
CircRNAs EXPRESSED IN NORMAL
HEMATOPOIESIS BY GENES OF THE
MLL RECOMBINOME
The MLL-rec analyzed here included MLL plus 94 TPGs
(Supplementary Table 1): 75 genes of rearrangements disclosed
by Meyer et al. (2018) and 19 genes previously reported
in the literature collected in the same study. Almost 93%
of 2,345 leukemia cases reported in Meyer et al. (2018)
resulted from MLL fusions with one of 12 highly recurrent
TPGs (AF4/AFF1, AF9/MLLT3, ENL/MLLT1, AF10/MLLT10,
BCS1L/PTD, ELL, AFDN/AF6/MLLT4, EPS15, AF1Q/MLLT11,
SEPT6, AF17/MLLT6, and SEPT9), that will be cited from now
on using the official gene name.
To obtain a data-driven picture of the circular transcriptome
of MLL-rec genes in the hematopoietic compartment, we
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analyzed our RNA-seq dataset regarding normal hematopoiesis
(available at GEO series ID: GSE110159 and upon request):
15 samples from healthy donors, including 3 of CD34+ cells
purified from cord blood, and 12 of B-, T-cells and monocytes
FACS sorted from PBMCs (4 different donors per cell type).
RNA-seq data were obtained from ribo-depleted RNA with
Illumina R© HiSeq2000 (average depth of 145 M paired end 100 nt
reads per sample, 66% of reads passed quality control). CircRNAs
were detected and quantified using CirComPara v0.3 (Gaffo
et al., 2017), implementing 6 circRNA detection methods (CIRI,
Findcirc, CIRCexplorer2+Star, CIRCexplorer2+Segemehl,
CIRCexplorer2+BWA, CIRCexplorer2+TopHat). CirComPara
identified 41,515 circRNAs expressed from 8,138 individual
genes. We focused on the subset of 16,606 circRNAs with high
expression in at least one cell type (maximum of the averages
per cell type in the top 40% highest values), which derived
from 5,170 genes.
For 25 of the 95 genes in the MLL-rec, no circRNAs were
detected in our dataset and 16 had only circRNAs expressed at
low level. Interestingly, 54 genes of the recombinome expressed
at least one abundant circRNA, for a total of 327 circRNAs
(Supplementary Table 2), which were further investigated.
The expression level of these circRNAs was not different
from the 16,005 circRNAs expressed by the 5,116 non-MLL-
rec genes of the human genome (Supplementary Figure 1).
MLL-rec genes expressed several circRNAs at very high levels:
the 33 most expressed circRNAs (Supplementary Figure 2)
derived from 21 genes, including AFF1 and EPS15, which
presented circRNAs overexpressed in stem cells; and SEPT6 and
SEPT9, whose circRNAs were detected only in mature cells, with
marked overexpression of circSEPT9 17:77402059–77402703:+
in monocytes. CircAFF3 2:100006632–100008932:- and circAFF4
5:132892164–132893118:-, both from MLL TPGs only found
in leukemias of the lymphoid lineage, were upregulated in
B-cells. Four genes contributed several circRNAs to the group
of the most highly expressed: 10 circPICALM were mostly
upregulated in monocytes, albeit circPICALM 11:86007542–
86026367:- and 11:86022367–86031611:- were more abundant
in stem cells; 2 circME2 were upregulated in stem cells; 2
circARHGAP26 were upregulated in monocytes; 2 circPDS5A
were upregulated in B-cells.
MLL-rec genes compared to non-MLL-rec genes had a
significantly larger number of circular isoforms per gene (6.06
vs. 3.13 circRNAs per gene in average; t-test p-value 2.317
E−04), with a distribution of the number of circRNAs per gene
significantly shifted toward higher values (Chi-squared test p-
value 1.791 E−06; Supplementary Figures 3A,B). Indeed, 9
of the recombinome genes expressed only one circRNA each,
and 45 (83%) had multiple circular isoforms in blood cells
(Figure 1A). The genes with the highest numbers of isoforms
were PICALM (31 circRNAs), AKAP13 (19), EPS15 (16), PDS5A
(16), ARHGAP26 (15), ITPR2 (15), EP300 (14), ME2 (14),
and MYO1F (10). Moreover, MLLT10, SEPT6 and AFF1 had 6
circRNAs each, and MLL3 expressed 4 circRNAs.
Similar numbers of circRNAs were expressed in the different
mature populations by MLL-rec (205, 244, and 210 in B-, T-cells
and in monocytes, respectively), and only 94 circRNAs in the
stem population (Supplementary Figure 4A). Apart from 44
circRNAs expressed in all cell types, 16 from 10 genes (CENPK,
LPP, ITPR2, TCF12, CLTC, FNBP1, FRYL, SEPT11, SEPT6,
and MLLT10) were detected only in stem cells (circCENPK
5:65528452–65529145:- was the most abundant), and 233 had
expression restricted to one or more mature populations, being
mostly detected in all the mature populations (80) or in
lymphocytes (40).
Most genes displayed cell type-specific alternative
circularization patterns (Supplementary Figure 4B). Of 16
stem cell-specific circRNAs, circCLTC 17:59668941–59669222:+
was expressed by a gene with circRNAs only in stem cells, and
15 derived from genes with other circular isoforms detected in
mature cell types. The three most abundant of the 16 different
circEPS15 had different expression profiles (Supplementary
Figure 4C): circEPS15 1:51402435–51408332:- was expressed in
all cell types with a slight upregulation in stem cells, whereas
circEPS15 1:51394381–51448135:- was upregulated only in
monocytes, and circEPS15 1:51405905–51408332:- was more
abundant in B- and T-cells than in monocytes, and not detected
in stem cells.
A scrutiny of the two main circRNA-indexing databases,
CircBase and circRNADB, showed that 2,433 circRNAs were
previously reported for 85 of 95 genes in the MLL-rec, including
all the 54 with highly expressed circRNAs, and all but ACER1
and PFDN4 of the 70 genes with circRNAs detected in our
data. Moreover, for 17 (out of 25) genes in the MLL-rec for
which we did not observe appreciable circRNA expression in
blood cells, the DBs reported circRNAs mostly in other tissues,
such as brain (e.g., ARHGEF17) or muscle (e.g., FLNC). Even
if a direct comparison of our data with data reported in the
DBs is not feasible, findings concordantly indicate that circRNAs
are expressed from the overwhelming majority of genes in the
MLL-rec, with complex patterns of alternative circularization
in many cases.
Of note, 63 new circRNAs were detected at high expression in
blood populations investigated in this study, which are currently
not annotated in the DBs (Supplementary Table 2). Newly
detected circRNAs derived from 26 genes of the MLL-rec,
including MLLT10, MLLT3, EPS15 and SEPT6, and comprised
15 circPICALM and circRNAs with expression restricted to stem
cells or to a specific mature population.
TRANSLOCATIONS CAN IMPACT
CircRNA EXPRESSION FROM
MLL/KMT2A AND TPGs
As described above, KMT2A and most of TPGs observed in
acute leukemias do express circRNAs in normal blood cells
(Figure 1A). In MLLre leukemias the rearrangement of KMT2A
with a TPG leads to the formation of a “fusion gene.” When
KMT2A is expressed, also the downstream partner gene may be
expressed resulting in a transcript that potentially is translated
in a fusion protein (Ayton and Cleary, 2001; So et al., 2003).
Alongside also f-circ may be produced from chimeric fusion
genes (Guarnerio et al., 2016), as reviewed in Bonizzato et al.
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FIGURE 1 | CircRNA expression by MLL/KMT2A and by MLL translocation partner genes (TPGs) in normal hematopoiesis can be altered in leukemic cells.
(A) Distribution of the number of circRNAs per gene expressed in normal blood cells by the MLL recombinome (the detail shows genes with multiple isoforms);
(B) MLL/KMT2A and a TPG can produce, in normal blood cells, several circRNAs; (C) CircRNA expression can be affected by the fusion: beyond the generation of
fusion-specific products (protein and circRNAs), the absence in the fusion gene of the exons undergoing circularization and/or of the intronic sequences flanking the
backsplicing with regulatory functions can deregulate or abolish circRNA expression; in addition, aberrant circRNAs can be generated by activation of “cryptic”
backsplicing sites.
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(2016). In addition, the breaking and fusion of KMT2A and TPGs
may alter the formation of circRNAs from exons proximal to
the breakpoint of the translocated genes. Information on the
KMT2A and TPGs specific exons that undergo circularization
in normal hematopoiesis (Figure 1B) is critical to understand
how a specific rearrangement can impact circRNA expression
(Figure 1C). The breakpoint position defines which genomic
regions are retained in the fusion gene, determining not only if
and how f-circ are generated. The breakpoint position can also
affect the circRNAs “normally” generated by the partner genes
influencing their expression level or possibly activating cryptic
backsplicing sites.
For KMT2A and of three of the main TPGs we further
examined in detail circRNAs expression in normal blood cells
in relation to potential breakpoint regions. In addition, we
provided preliminary data of MLLre leukemia using RNA-
seq data of the THP1 cell line with KMT2A-MLLT3 (MLL-
AF9) fusion (Guarnerio et al., 2016) and unpublished data of
two specimens of infant ALL with KMT2A-MLLT1 (MLL-ENL)
fusions (Supplementary Table 3).
In normal hematopoiesis, KMT2A produced 5 different
circRNAs (Figure 2A). The most abundant circKMT2A
(11:118481715–118482495:+; exons 7–8) was expressed in all
mature populations, with upregulation in both B- and T-cells,
while it was absent in the stem population, in which two other
circKMT2A isoforms were detected. The formation of two wild
type circKMT2A isoforms (exons 5–8 and 7–8) are potentially
perturbed in MLLre leukemias, considering that the recurrent
breakpoint region includes exon 8. The other three circKMT2A
expressed in normal hematopoiesis (exons 12–16, 17–23, 21–23)
will probably not be formed from the fusion gene, since they
originate from exons not retained in most rearrangements. Thus,
all circRNAs highly expressed in normal cells by KMT2A may
be downregulated or even absent in the leukemic cells. In line,
none of the circRNAs expressed in normal hematopoiesis by
KMT2A was detected, neither in the THP1 cell line (in which
two fusion circRNAs were previously detected by RT-PCR,
and albeit supported by few reads, from RNA-seq data), nor in
any of the two samples with KMT2A-MLLT1 fusion. Of note,
KMT2A exons 5 or 7 are the starting ends backspliced both in
normal hematopoiesis (joined with exon 8 in two of the five
observed circKMT2A isoforms) and in THP1 cells (joined with
MLLT3 exon 6 in the two f-circM9 isoforms) (Guarnerio et al.,
2016). If and how the reported oncogenic potential of f-circM9
(KMT2A exon 7 – MLLT3 exon 6) is related to the function of
the most expressed circKMT2A (KMT2A exons 7–8), that is fully
contained in the f-circM9, remains to be determined.
The three TPGs most recurrent in acute leukemias (AFF1,
MLLT3, MLLT1) expressed one to 5 circRNAs each in normal
hematopoiesis (Figures 2B–D). AFF1 presented 5 circRNAs,
with circAFF1 4:87046166–87047594:+ (exons 2–3) contributing
alone to 90% of circular expression of the gene. The same
circAFF1 was one of the most expressed in the sample set, it
presented a remarkable upregulation in stem cells compared to
mature cells according to our data, and was found upregulated in
common lymphoid precursors and in monocytes (Nicolet et al.,
2018). The AFF1 recurrent breakpoint region position in MLLre
leukemias reveals that this circAFF1 will likely not be generated
from the chimeric gene. The expression of the other 4 circAFF1
will depend on the exact position of the breakpoint (Figure 2B).
MLLT3 had 4 circular isoforms, almost all specific of
T-cells. The second most expressed circMLLT3 contains part
of intron 4, as observed for other circRNAs (Li Z. et al.,
2015). These circRNAs will not be generated from the fusion
gene due to the position of the breakpoints, either falling
within the sequence undergoing circularization or eliminating all
circularized exons from the fusion transcripts (Figure 2C). None
of the T-specific circMLLT3 isoforms was detected in KMT2A-
MLLT3 THP1 cells.
Also circMLLT1 9:6230570–6274759:- (exons 2–4), expressed
in mature populations, will not be generated from the KMT2A-
MLLT1 derivative, since the breakpoints of t(11,19) leukemias
either abolish the MLLT1 exons undergoing circularization or
fall in the intron flanking the backspliced exon 2. In line with
our assumption, this circRNA was not detected in leukemic cells
(Figure 2D) with two different KMT2A-MLLT1 fusions (KMT2A
exon 9 – MLLT1 exon 6, and KMT2A exon 8 – MLLT1 exon 4
fusions, Supplementary Table 3).
Here, we analyzed one of the main KMT2A-TPG fusions,
and the translocations indeed impacted circRNAs expressed from
KMT2A and its TPG. Highly informative data on leukemias
with KMT2A-MLLT1 fusions were fully in agreement with
observations (based on a lower depth) in THP1 cells. Little is
known about the other TPG-KMT2A derivatives.
To generalize, based on circRNA and breakpoint respective
position, four scenarios can occur: (1) The exons undergoing
circularization are retained in the KMT2A-TPG derivative (e.g.,
exons in the 5′ region of KMT2A or in the 3′ region of
the TPG retained in the fusion gene), circRNAs can be still
generated; (2) The exons undergoing circularization are not
retained, the circRNAs can be abolished; (3) The breakpoint is
located between the backspliced ends, the absence in the fusion
gene of one or more exons normally undergoing circularization
will prevent the formation of circRNAs, possibly favoring the
generation of f-circ; (4) The breakpoint is located in an intron
flanking one of the backsplice ends abolishing specific in cis
sequence elements (Alu and inverted repeats) that favor the
backsplicing (Jeck et al., 2013; Bonizzato et al., 2016), and/or
sequences recognized by in trans regulatory factors, such as
QKI and ADAR1, which promotes (Conn et al., 2015) and
suppresses (Rybak-Wolf et al., 2015) circularization, respectively.
We are well aware that our model of how translocations can
impact expression of circRNAs from fused genes is hampered
by simplicity. Position-effects, as well as deep genome-wide
epigenetic and transcriptional deregulation in leukemic cells
can affect circRNAs expressed from the fused genes as well as
circRNAs from other loci.
CONCLUSION AND FUTURE
DIRECTIONS
Data emerging from recent literature and from the present study
collectively show that KMT2A and TPGs express many circRNAs,
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FIGURE 2 | CircRNAs expressed by KMT2A and 3 TPGs among the most recurrent in acute leukemias. The picture includes a schematic diagram of exon/intron
structure of KMT2A gene (A) and of the 3 selected TPGs: AFF1 (B), MLLT3 (C), MLLT1 (D), that give rise to fusion genes in acute leukemias; exon numbering and
relevant breakpoint regions (blue bars) are indicated for each gene (reference transcripts: ENST00000534358.6, ENST00000307808.10, ENST00000380338.8, and
ENST00000252674.8); the most expressed circRNAs are shown by red arches, indicating the position of the backsplice ends. For each gene, different letters
identify circRNAs for which the barplot shows average expression in the four normal blood cell populations (S, stem cells; B, B-cells; T, T-cells; M, monocytes), as
well as in leukemic cells bearing KMT2A-MLLT1 fusion (MLL-ENL ALL).
possibly playing important functions and being perturbed in
cells bearing rearrangements. According to our observations,
depending on the position of the breakpoint respective to the
backspliced sequences, translocations can impact expression
of circRNAs in addition to generating f-circ. Our data on
circRNAs expressed from genes of the MLL recombinome are
instrumental to analyze alterations of circRNAs from rearranged
genes of MLLre leukemias and f-circ generation. It is known
that f-circ can be oncogenic, but the involved mechanisms
remain essentially unknown. F-circ and the other circRNAs
expressed from KMT2A and TPGs might share part of their
sequences and play similar functions (e.g., through common
protein or nucleic acids interactors, or due to overlapping
coding potential). F-circ were previously shown to reinforce
the oncogenic potential of fusion proteins, perhaps cooperating
to the same mechanisms (Babin et al., 2018). A parallel line
of evidence showed that loss of both KMT2A and KMT2D
impair survival pathways in leukemic cells (Chen et al., 2017),
implicating them in oncogenesis. In this view, beyond f-circ,
also circRNAs generated from the non-translocated alleles are
critical candidates to be investigated for participation to disease
mechanisms. Further, f-circ and circRNAs in general share exons
with linear transcripts, and circularization is associated with
exon skipping (Kelly et al., 2015). The equilibrium perturbed
by translocations can involve a series of transcripts including
“normal” as well as aberrant circular and linear transcripts, all
linked in an intricate network of similar sequences and functions
and interdependent biogenesis.
In conclusion, next to the studies of fusion proteins as
oncogenic drivers of leukemias with MLL rearrangements, we
stress the need of a molecular characterization of circRNAs
expressed by fusion genes, KMT2A itself and its TPGs. A first
direction could be to clarify the participation of circRNAs to the
molecular complexes involving KMT2A, and to define circRNA
molecular interactions with regulators, such as microRNAs, of
KMT2A or of its interactors involved in leukemogenesis. The
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perspective emerging from this pilot study on MLLre acute
leukemia is presumably valid for most of the driver chromosomal
fusions occurring in cancer cells.
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